Literature DB >> 29885541

Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?

Cristina Belizna1, Ljudmila Stojanovich2, Jan Willem Cohen-Tervaert3, Céline Fassot4, Daniel Henrion4, Laurent Loufrani4, Gyorgy Nagy5, Christian Muchardt6, Milena Hasan7, Marie Noelle Ungeheuer8, Laurent Arnaud9, Jaume Alijotas-Reig10, Enrique Esteve-Valverde11, Ferdinando Nicoletti12, Patrick Saulnier13, Alban Godon14, Pascal Reynier15, Jean Marie Chrétien13, Laura Damian16, Loukman Omarjee17, Guillaume Mahé17, Marc Antoine Pistorius18, Pier Luigi Meroni19, Katrien Devreese20.   

Abstract

Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Antiphospholipid syndrome; Primary antiphospholipid syndrome; Secondary antiphospholipid syndrome

Mesh:

Substances:

Year:  2018        PMID: 29885541     DOI: 10.1016/j.autrev.2018.01.027

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  6 in total

1.  Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China.

Authors:  Zhuochao Zhou; Jialin Teng; Yue Sun; Honglei Liu; Xiaobing Cheng; Yutong Su; Chengde Yang; Junna Ye
Journal:  Clin Rheumatol       Date:  2019-07-09       Impact factor: 2.980

Review 2.  Low molecular weight heparin monotherapy for recurrent abortion with antiphospholipid system: A protocol of a systematic review.

Authors:  Lei Ni; Xue-Qian Sun; Dong-Xu Zhao; Zi-Wei Zhu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.889

3.  Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome.

Authors:  Lorena Álvarez-Rodríguez; Víctor Martínez-Taboada; Jaime Calvo-Alén; Iñaki Beares; Ignacio Villa; Marcos López-Hoyos
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

4.  Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome.

Authors:  Valeria Manganelli; Simona Truglia; Antonella Capozzi; Cristiano Alessandri; Gloria Riitano; Francesca Romana Spinelli; Fulvia Ceccarelli; Silvia Mancuso; Tina Garofalo; Agostina Longo; Guido Valesini; Maurizio Sorice; Fabrizio Conti; Roberta Misasi
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

5.  Relationship Between Gender Differences and Clinical Outcome in Patients With the Antiphospholipid Syndrome.

Authors:  Simona Truglia; Antonella Capozzi; Silvia Mancuso; Valeria Manganelli; Luca Rapino; Gloria Riitano; Serena Recalchi; Serena Colafrancesco; Fulvia Ceccarelli; Tina Garofalo; Cristiano Alessandri; Agostina Longo; Roberta Misasi; Fabrizio Conti; Maurizio Sorice
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

6.  Risk of Systemic Lupus Erythematosus in Patients With Anti-phospholipid Syndrome: A Population-Based Study.

Authors:  Hsin-Hua Chen; Ching-Heng Lin; Wen-Cheng Chao
Journal:  Front Med (Lausanne)       Date:  2021-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.